Clinical trials: Aripiprazole
Bipolar I Disorder
A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
To investigate the safety and efficacy of long-term administration of aripiprazole by performing extended administration of the treatment administered in the preceding multicenter, double-blind, placebo-controlled, parallel…
- Trial name
- NCT00606177
- Testing
- Aripiprazole
- Where
- 12 sites in China, Japan and 2 more
- Volunteers
- 99 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Bipolar Disorder
Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder
This study evaluated whether lithium included as part of optimized medication treatment improved overall level of illness, symptoms of mania and depression, and quality of life in people with bipolar disorder.
- Trial name
- LiTMUS (NCT00667745)
- Testing
- Lithium Carbonate, Optimized Treatment (OPT)
- Where
- 6 sites in United States
- Volunteers
- 283 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are…
- Trial name
- NCT00209027
- Testing
- fMRI, Aripiprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Emory University
Autistic Disorder
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
The Biomarkers in autism of aripiprazole and risperidone treatment (BAART) project will provide evidence-based guidance in the selection and monitoring of drug treatment of autism.
- Trial name
- BAART (NCT01333072)
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical University of South Carolina
Schizophrenia
Metabolic Signatures and Biomarkers in Schizophrenia
We plan to use a metabolomics lipid platform to map biochemical signatures in unmedicated schizophrenic patients prior to and 4 weeks post treatment with the antipsychotic drug aripiprazole and compare that to lipid perturbations…
- Trial name
- NCT00466310
- Testing
- Aripiprazole, Risperidone, Healthy volunteers
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Duke University
Diabetes
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.
- Trial name
- NCT00895921
- Testing
- Olanzapine, Aripiprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Device Latency
Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
The purpose of this study is to determine the accuracy of IEM detection by the MIND1 System by completing a series of Patch applications and IEM ingestions in the clinic.
- Trial name
- OSMITTER (NCT02404532)
- Testing
- MIND1 System
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
C-Cog in Early Course Schizophrenia Study
The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.
- Trial name
- NCT05662306
- Testing
- Aripiprazole Lauroxil, Computerized cognitive and functional skills training
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Schizophrenia
A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
This study will evaluate the safety, tolerability, efficacy and pharmacokinetics of aripiprazole intramuscular (IM) depot multiple doses every 4 weeks in adult patients with schizophrenia.
- Trial name
- NCT01870999
- Testing
- aripiprazole IM depot, aripiprazole tablets
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due…
- Trial name
- i-FANS (NCT01207414)
- Testing
- iloperidone
- Where
- 59 sites in United States
- Volunteers
- 501 people
- Sponsor
- Novartis
Bipolar I Disorder
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
The primary objective of this trial is to evaluate the clinical efficacy and safety of aripiprazole in comparison to placebo in patients with Bipolar I Disorder experiencing a manic or mixed episode.
- Trial name
- NCT00606281
- Testing
- Aripiprazole
- Where
- 12 sites in China, Japan and 2 more
- Volunteers
- 258 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia
The purpose of this study is to determine whether aripiprazole injection into the shoulder or the buttocks produces similar effects in the body
- Trial name
- NCT01646827
- Testing
- Aripiprazole IM Depot
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette's Disorder, Tic Disorder
Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to determine safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01727713
- Testing
- Aripiprazole
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 110 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
- Trial name
- NCT00149734
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.
- Trial name
- STAR-1 (NCT00509067)
- Testing
- Galantamine, CDP-choline, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Georgetown University
Schizophrenia
Oral Aripiprazole Open-Label Rollover Study
The purpose of this study is to test the long-term safety and tolerability of oral aripiprazole in adolescent patients with schizophrenia.
- Trial name
- NCT01001702
- Testing
- Aripiprazole
- Where
- 15 sites in Argentina, Croatia and 4 more
- Volunteers
- 85 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
- Trial name
- PROACTIVE (NCT00330863)
- Testing
- Risperidone microspheres, Risperidone, Olanzapine
- Where
- 8 sites in United States
- Volunteers
- 357 people
- Sponsor
- Northwell Health
Aggression, Attention Deficit-Hyperactivity
Metabolic Effects of Antipsychotics in Children
The project aims to describe and compare the outcome of 12 weeks of prospective, randomized treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle, liver and adipose tissue, abdominal fat…
- Conditions
- Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders
- Trial name
- MEAC (NCT00205699)
- Testing
- risperidone, olanzapine, aripiprazole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Schizophrenia Relapse
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction
To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.
- Trial name
- NCT03019887
- Testing
- reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
- Volunteers
- 139 people
- Sponsor
- Juntendo University
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.